In the chronic phase of AD, a mixed immune response is observed, involving Th1, Th17, and Th22 lymphocytes, whose cytokines—such as IFN-γ, IL-17, and IL-22—contribute to the persistence of inflammation, deterioration of skin barrier function, and exacerbation of clinical symptoms [84]. Here, IL17A is linked to Alzheimer disease.